Cargando…

Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections

Dipeptidylpeptidase (DPP)-4 is a key regulator of the incretin system. For several years DPP-4 inhibitors in addition to GLP-1 analogues are of major importance in the clinical management of obesity and type 2 diabetes. DPP-4 is also known as CD26 and represents a membrane bound protease on the surf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schlicht, Kristina, Rohmann, Nathalie, Geisler, Corinna, Hollstein, Tim, Knappe, Carina, Hartmann, Katharina, Schwarz, Jeanette, Tran, Florian, Schunk, Domagoj, Junker, Ralf, Bahmer, Thomas, Rosenstiel, Philip, Schulte, Dominik, Türk, Kathrin, Franke, Andre, Schreiber, Stefan, Laudes, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503441/ https://www.ncbi.nlm.nih.gov/pubmed/32958905 http://dx.doi.org/10.1038/s41366-020-00689-y

Ejemplares similares

Correction: Circulating levels of soluble Dipeptidylpeptidase-4 are reduced in human subjects hospitalized for severe COVID-19 infections
por: Schlicht, Kristina, et al.
Publicado: (2021)

Dipeptidylpeptidase (DPP)-4 inhibitor therapy increases circulating levels of anti-inflammatory soluble frizzle receptor protein (sFRP)-5 which is decreased in severe COVID-19 disease
por: Brandes, Juliane, et al.
Publicado: (2022)

Brief Research Report: Serum clara cell 16 kDa protein levels are increased in patients hospitalized for severe SARS-CoV-2 or sepsis infection
por: Rohmann, Nathalie, et al.
Publicado: (2022)

BMI, Alcohol Consumption and Gut Microbiome Species Richness Are Related to Structural and Functional Neurological Abnormalities
por: Geisler, Corinna, et al.
Publicado: (2021)

A dietary carbohydrate – gut Parasutterella – human fatty acid biosynthesis metabolic axis in obesity and type 2 diabetes
por: Henneke, Lea, et al.
Publicado: (2022)

Cohort profile: the Food Chain Plus (FoCus) cohort
por: Geisler, Corinna, et al.
Publicado: (2022)

Differential Effects of Obesity, Hyperlipidaemia, Dietary Intake and Physical Inactivity on Type I versus Type IV Allergies
por: Rohmann, Nathalie, et al.
Publicado: (2022)

Effect of various weight loss interventions on serum NT-proBNP concentration in severe obese subjects without clinical manifest heart failure
por: Hollstein, Tim, et al.
Publicado: (2021)

Microbiota in Health and Disease—Potential Clinical Applications
por: Laudes, Matthias, et al.
Publicado: (2021)

Precision Nutrition in Chronic Inflammation
por: Demetrowitsch, Tobias J., et al.
Publicado: (2020)

Rapid response to leptin therapy in a FPLD patient with a novel PPARG missense variant
por: Melzer, Fiona, et al.
Publicado: (2021)

Okuläre Manifestationen bei COVID-19-Patienten
por: Hösel, Kristin, et al.
Publicado: (2022)

Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin
por: Zimdahl, Heike, et al.
Publicado: (2014)

Activity Staining and Inhibition Characterization of Dipeptidylpeptidase-III Enzyme from Goat Brain
por: Attri, Pooja, et al.
Publicado: (2011)

The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin
por: Aroor, Annayya R., et al.
Publicado: (2018)

Dipeptidylpeptidase 4 promotes survival and stemness of acute myeloid leukemia stem cells
por: Wang, Chen, et al.
Publicado: (2023)

Relapsing Syndrome of Inappropriate Antidiuretic Hormone Production Responding to Tolvaptan Treatment in a Patient With a Micronodular Formation of the Posterior Pituitary Gland
por: Reinke, Lennart M., et al.
Publicado: (2023)

Vitamin C and Omega-3 Fatty Acid Intake Is Associated with Human Periodontitis—A Nested Case-Control Study
por: Mewes, Louisa, et al.
Publicado: (2022)

Counteracting the enzymatic activity of dipeptidylpeptidase 4 for potential therapeutic advantage, with an emphasis on cord blood transplantation
por: Broxmeyer, Hal E.
Publicado: (2013)

Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China
por: Lin, Wen-Qiang, et al.
Publicado: (2021)

Beneficial Effects of a Dietary Weight Loss Intervention on Human Gut Microbiome Diversity and Metabolism Are Not Sustained during Weight Maintenance
por: Heinsen, Femke-Anouska, et al.
Publicado: (2017)

Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours
por: Dohi, Osamu, et al.
Publicado: (2009)

Evaluation of Pharmacokinetic Drug Interactions Between Gemigliptin (Dipeptidylpeptidase-4 Inhibitor) and Glimepiride (Sulfonylurea) in Healthy Volunteers
por: Choi, Hee Youn, et al.
Publicado: (2014)

Rapid and sensitive detection of early esophageal squamous cell carcinoma with fluorescence probe targeting dipeptidylpeptidase IV
por: Onoyama, Haruna, et al.
Publicado: (2016)

Manipulation of dipeptidylpeptidase 10 in mouse and human in vivo and in vitro models indicates a protective role in asthma
por: Zhang, Youming, et al.
Publicado: (2018)

Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity
por: Posadas-Sánchez, Rosalinda, et al.
Publicado: (2021)

Alopecia areata universalis nach Sitagliptin-Einnahme: Mögliche immunologische Wirkung von Dipeptidylpeptidase-4-Inhibitoren?
por: Kohlmann, Johannes, et al.
Publicado: (2020)

Reorganize and survive—a recommendation for healthcare services affected by COVID-19—the ophthalmology experience
por: Petrovski, Beáta Éva, et al.
Publicado: (2020)

Dipeptidylpeptidase-IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats
por: Tarantola, E., et al.
Publicado: (2012)

Comparative Effectiveness of Dipeptidylpeptidase-4 Inhibitors in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison
por: Craddy, Paul, et al.
Publicado: (2014)

High mobility group box 1 contributes to wound healing induced by inhibition of dipeptidylpeptidase 4 in cultured keratinocytes
por: Sinagra, Tiziana, et al.
Publicado: (2015)

Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors
por: Ray, Chin-Ying, et al.
Publicado: (2021)

First data on COVID-19 morbidity and mortality in patients with rheumatic disease from South Korea
por: Schreiber, Karen, et al.
Publicado: (2021)

COVID-19: ACT trials for colchicine and antithrombotic therapies
por: Barco, Stefano, et al.
Publicado: (2022)

Women with gout and COVID-19—an unfortunate combination?
por: Nissen, Christoffer B, et al.
Publicado: (2022)

Comment on Favresse et al. Persistence of Anti-SARS-CoV-2 Antibodies Depends on the Analytical Kit: A Report for Up to 10 Months after Infection. Microorganisms 2021, 9, 556
por: Schulte-Pelkum, Johannes
Publicado: (2021)

IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition
por: Alicke, Bruno, et al.
Publicado: (2022)

Constitutive expression of CD26/dipeptidylpeptidase IV on peripheral blood B lymphocytes of patients with B chronic lymphocytic leukaemia
por: Bauvois, B, et al.
Publicado: (1999)

High-dose sitagliptin for systemic inhibition of dipeptidylpeptidase-4 to enhance engraftment of single cord umbilical cord blood transplantation
por: Farag, Sherif S., et al.
Publicado: (2017)

If there is not one cure for schizophrenia, there may be many
por: Seah, Carina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jpll2e5p6hs258asgttvpgslqr